See the DrugPatentWatch profile for cosentyx

While Cosentyx (secukinumab) has proven to be an effective treatment for various conditions such as psoriasis, ankylosing spondylitis, and psoriatic arthritis [1], lowering the dosage without medical supervision may pose risks.

Cosentyx's recommended dosage is based on clinical trials and FDA approval, which ensure the drug's safety and efficacy [1]. Altering the dosage can lead to reduced therapeutic effectiveness, increased risk of disease progression, and potential adverse reactions [2].

Moreover, drug resistance can develop if the dosage is not maintained as prescribed, further reducing the drug's long-term effectiveness [3].

It is crucial to consult healthcare professionals before making any changes to a medication regimen, as they can provide personalized advice based on individual medical history and current health status [4].

In summary, lowering Cosentyx dosage for adults without medical guidance can lead to potential risks, including reduced effectiveness, disease progression, and adverse reactions.

Sources:
[1] <https://www.drugs.com/cosentyx.html>
[2] <https://www.ncbi.nlm.nih.gov/books/NBK221766/>
[3] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179583/>
[4] <https://www.mayoclinic.org/diseases-conditions/psoriasis/in-depth/psoriasis-treatment/art-20046041>